ES2173047A1 - Procedimiento para la obtencion de las diferentes fracciones de guayaba atomizada y su uso para el tratamiento de la diabetes mellitus tipo ii - Google Patents

Procedimiento para la obtencion de las diferentes fracciones de guayaba atomizada y su uso para el tratamiento de la diabetes mellitus tipo ii

Info

Publication number
ES2173047A1
ES2173047A1 ES200100657A ES200100657A ES2173047A1 ES 2173047 A1 ES2173047 A1 ES 2173047A1 ES 200100657 A ES200100657 A ES 200100657A ES 200100657 A ES200100657 A ES 200100657A ES 2173047 A1 ES2173047 A1 ES 2173047A1
Authority
ES
Spain
Prior art keywords
guava
procedure
obtaining
treatment
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES200100657A
Other languages
English (en)
Other versions
ES2173047B1 (es
Inventor
Carrillo De Albornoz Jos Osuna
Garcia Maria Jose Lopez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratorio de Aplicaciones Farmacodinamicas SA
Original Assignee
Laboratorio de Aplicaciones Farmacodinamicas SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorio de Aplicaciones Farmacodinamicas SA filed Critical Laboratorio de Aplicaciones Farmacodinamicas SA
Priority to ES200100657A priority Critical patent/ES2173047B1/es
Priority to EP02380065A priority patent/EP1245234A1/en
Publication of ES2173047A1 publication Critical patent/ES2173047A1/es
Application granted granted Critical
Publication of ES2173047B1 publication Critical patent/ES2173047B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Botany (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se relaciona con nuevos agentes con actividad hipoglucemiante, derivados de la guayaba de la especie Psidium guajaba, procedimiento de obtención de tales agentes caracterizado porque comprende las etapas: a) deshidratar la guayaba; b) someter la guayaba deshidratada a extracción utilizando metanol, hexano, o cloroformo como disolventes, para así obtener respectivamente las distintas fracciones de la guayaba; c) aislar las fracciones metanólica, hexánica y clorofórmica así obtenidas, con actividad hipoglucemiante; y d) someter el resto de la guayaba a ebullición con agua destilada, para obtener tras la sedimentación la fracción acuosa con actividad hipoglucemiante, y uso de los mismos para el tratamiento de la Diabetes Mellitus tipo II.
ES200100657A 2001-03-21 2001-03-21 Procedimiento para la obtencion de las diferentes fracciones de guayaba atomizada y su uso para el tratamiento de la diabetes mellitus tipo ii Expired - Fee Related ES2173047B1 (es)

Priority Applications (2)

Application Number Priority Date Filing Date Title
ES200100657A ES2173047B1 (es) 2001-03-21 2001-03-21 Procedimiento para la obtencion de las diferentes fracciones de guayaba atomizada y su uso para el tratamiento de la diabetes mellitus tipo ii
EP02380065A EP1245234A1 (en) 2001-03-21 2002-03-20 Procedure for obtaining the different fractions of atomised spanish guava and their use for the treatment of type II diabetes mellitus

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200100657A ES2173047B1 (es) 2001-03-21 2001-03-21 Procedimiento para la obtencion de las diferentes fracciones de guayaba atomizada y su uso para el tratamiento de la diabetes mellitus tipo ii

Publications (2)

Publication Number Publication Date
ES2173047A1 true ES2173047A1 (es) 2002-10-01
ES2173047B1 ES2173047B1 (es) 2004-01-01

Family

ID=8497167

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200100657A Expired - Fee Related ES2173047B1 (es) 2001-03-21 2001-03-21 Procedimiento para la obtencion de las diferentes fracciones de guayaba atomizada y su uso para el tratamiento de la diabetes mellitus tipo ii

Country Status (2)

Country Link
EP (1) EP1245234A1 (es)
ES (1) ES2173047B1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT502717A1 (de) * 2005-11-09 2007-05-15 Omnica Gmbh Pharmazeutische verwendung einer verbindung
US7611739B2 (en) 2006-01-06 2009-11-03 Amerilab Technologies, Inc. Method of using guava extract and composition including guava extract
US20090004270A1 (en) 2006-01-06 2009-01-01 Amerilab Technologies, Inc. Method of using guava extract

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63283563A (ja) * 1987-05-18 1988-11-21 Morishige Okinaga グァバ茶の製造方法
JPH10202002A (ja) * 1997-01-23 1998-08-04 Bizen Kasei Kk 改良グアバ葉エキス抽出法
JP2000239177A (ja) * 1999-02-22 2000-09-05 Sakamoto Yakusoen:Kk 抗糖尿病剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6056923A (ja) * 1983-09-06 1985-04-02 Bizen Kasei Kk グアバ葉エキスの抽出方法
EP0154530A2 (en) * 1984-03-01 1985-09-11 Reuben Judah Robinson Medicinal substance
JPS6137731A (ja) * 1984-07-31 1986-02-22 Bizen Kasei Kk グアバ葉エキスを有効成分とする経口糖尿病薬
ATE99546T1 (de) * 1989-05-01 1994-01-15 Alkermes Inc Verfahren zur herstellung von kleinen partikeln von biologisch aktiven molekuelen.
US5264228A (en) * 1992-06-01 1993-11-23 Nestec S.A. Preparation of compositions for making cocoa beverages
JP3129371B2 (ja) * 1993-11-04 2001-01-29 ポーラ化成工業株式会社 浴用剤
JPH092969A (ja) * 1995-06-20 1997-01-07 O S Kogyo Kk アレルギー疾患治療剤

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63283563A (ja) * 1987-05-18 1988-11-21 Morishige Okinaga グァバ茶の製造方法
JPH10202002A (ja) * 1997-01-23 1998-08-04 Bizen Kasei Kk 改良グアバ葉エキス抽出法
JP2000239177A (ja) * 1999-02-22 2000-09-05 Sakamoto Yakusoen:Kk 抗糖尿病剤

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
"Anti-hyperglycemic effect of some edible plants". Journal of Ethnopharmacology, 1995, vol 48, no 1, paginas 25-32. HSU, F.-L., et al. "Investigation in rats of the Antihyperglycaemic effect of plant extracts used in Taiwan for the treatment of Diabetes Mellitus". Phytotherapy Research, 1992. Vol. 6, no 2, paginas 108-111. *
BASE DE DATOS BIOSIS en EPOQUE. AN-PREV198682006911 MARUYAMA, Y. et al. "Study on Psidium guajava I. Anti-diabetic effect and effective components of the leaf of Psidium guajava Part 1". Resumen. Shoyakugaku Zasshi, 1985. *
BASE DE DATOS BIOSIS en EPOQUE. AN-PREV199800484808 DEGUCHI, Y. et al. "Effects of extract of guava leaves on the development of diabetes in the db/db mouse and the postprandial blood glucose of human subjects". Resumen. Nippon Nogeikagaku Kaishi, Agosto 1998. *
CHENG, J.-T. et al. "Hypoglycemic effect of Guava Juice in mice and human subjects". American Journal of Chinese Medicine, 1983. Vol. 11, no 1-4, paginas 74-76. *
DEGUCHI, Y. et al. "Effectiveness of consecutive ingestion and excess intake of guava leaves tea in human volunteers". Nippon Shokuhin Shinzozai Kenkyukaishi, 2000. Vol. 3, no 1, paginas 19-28 *
KEJI, C. "Understanding and Treatment of Diabetes Mellitus by Traditional Chinese Medicine". American Journal of Chinese Medicine, 1981. Vol. 9, no 1, paginas 93-94. *
OBATOMI, D.K. et al. "Anti-diabetic properties of the African mistletoe in Streptozotocin-induced diabetic rats". Journal of Ethnopharmacology, 1994. Vol. 43, no 1, paginas 13-17. *
ROMAN-RAMOS, R. et al. "Anti-hyperglycemic effect of some edible paginas 25-32. *

Also Published As

Publication number Publication date
EP1245234A1 (en) 2002-10-02
ES2173047B1 (es) 2004-01-01

Similar Documents

Publication Publication Date Title
WO2003049702A8 (en) Vanilloid receptor ligands and their use in treatments
ECSP045081A (es) Derivados de 1,8-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados
MXPA04003668A (es) Inhibidores de fosfodiesteresa de tipo 4 y usos de los mismos.
GEP20094780B (en) Prostaglandin nitrooxyderivatives
FI956014A0 (fi) Nona- ja dekapeptidien käyttö lääkkeen valmistamiseksi AIDS-sairauden hoitoon
CL2004001174A1 (es) Composicion farmaceutica que comprende: 1-(4-fluorofenil)-3(r)-[3-(4-fluorofenil)-3(s)-hidroxipropil]-4(s)-(4-hidroxifenil)-2-acetidinona (ezetimiba) y excipientes; y su uso en el tratamiento y/o prevencion de aterosclerosis, hipercolesterolemia, dia
AU2162599A (en) New piperidinyl-substituted pyridylalkane, alkene and alkine carboxamides
GB0111186D0 (en) Novel compounds
CA2336833A1 (en) Remedy with antidepressant effects
UA85368C2 (ru) Применение остеопонтина для лечения и/или предотвращения неврологического заболевания
PT1387681E (pt) Compostos antivirais
WO2001027118A3 (de) Bicyclische imidazo-5-yl-aminderivate
WO2004031129A3 (en) Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection
WO2003005880A3 (en) Replikin peptides and uses thereof
CA2412789A1 (en) Compositions for improving mental concentration
AU9678501A (en) Pharmaceutical solutions of modafinil compounds
ZA985993B (en) Pharmaceutical compositions
ATE333901T1 (de) Pharmazeutische zusammensetzung eines biguanin (metformin) und arginin
EA200801714A1 (ru) Нетоксичные для нервной ткани плазминоген-активирующие факторы для лечения инсульта
WO2002024867A3 (en) Novel compositions and methods for lymphoma and leukemia
WO2003057719A3 (en) Methods of modulating localization and physiological function of ip3 receptors
ATE393624T1 (de) Verwendung von sesquiterpene enthaltenden zusammenstellungen zur behandlung von krebs
EP1260221A3 (en) Combination treatment for depression and anxiety
WO2003020371A3 (en) Potentiator composition comprising a terpene for enhancing a therapeutical effect of antitumoral agents in the treatment of cancer
WO2003043565A3 (en) Methods for diagnosis and treatment of diseases associated with altered expression of nrf2

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20021001

Kind code of ref document: A1

Effective date: 20021001

FG2A Definitive protection

Ref document number: 2173047B1

Country of ref document: ES

FD2A Announcement of lapse in spain

Effective date: 20211119